Supervisory Board
ARCH is a foundation and, during its start-up phase, is being funded by ReumaNederland. To ensure that the foundation achieves its expected goals, ARCH has a supervisory board with two members:

Prof. C.G.M. Kallenberg (internist, emeritus professor of clinical immunology, UMCG)
Mr H.M. le Clerq (on behalf of ReumaNederland, previously member of the ReumaNederland Supervisory Board and LUMC Executive Board)

Executive Board
The executive board represents and manages ARCH and is responsible for the financial management of the platform. Dr Hein Bernelot Moens is chair and Prof. Jaap van Laar second member. Both are also members of the ARCH project team.

Project Team
The project team supports the board and is responsible for attaining the intended results of the ARCH foundation.

Achtergrond  Droom/ambitie

Hein Bernelot Moens
Executive Board

Hein is rheumatologist at ZGT and chair of the Dutch Society for Rheumatology. He has worked for the Jan van Breemen Institute in Reade, VUmc and AMC in Amsterdam, the National Library of Medicine, Bethesda, Maryland, and MST in Enschede. “My dream is for all patients with rare arthritis conditions to get access to the best expertise simply and quickly.”

Jaap van Laar
Executive Board

Jaap is rheumatologist and Head of the Department of Rheumatology and Clinical Immunology at UMC Utrecht. Jaap has also been affiliated with LUMC, the National Institutes of Health in Bethesda (US) and Newcastle University (UK). “I hope that patients with rare arthritis conditions will soon receive demonstrably better care in our country than in all our neighbouring countries.”

Han de Ruiter
Advisor for innovation
product development

Han has 33 years’ experience in the financial sector holding various management and director’s positions in marketing, sales, strategy, product development and customer centricity. His role as advisor contributes to client innovativeness. “ARCH will really make a difference for this group of patients in terms of speed of diagnosis and proper personalized treatment.”

Casper Schoemaker
Advisor for patient participation

Casper is advisor for patient participation in the Department of Paediatric Rheumatology at Wilhelmina Children’s Hospital UMC Utrecht. He is also representative of the Dutch Juvenile Arthritis Association, experiential expert in the scientific advisory committee for the Dutch Lung Foundation and senior researcher for the RIVM. “In collaboration with people with a rare arthritis condition, I want to ensure ARCH can make a difference in their day-to-day lives.”

Madelon Vonk
Chair working group Systemic Sclerosis

Madelon is rheumatologist in Radboud UMC. She specialises in complex autoimmune disease and combines patient care with scientific research and teaching students and rheumatologists. Madelon has worked in the Groene Hart Hospital in Gouda and the CWZ and St Maartens Clinic in Nijmegen. “I want to be able to provide high-quality, accessible care for all those with systemic sclerosis in the Netherlands.”

Onno Teng
Chair working group ANCA Vasculitis

Onno is internist-nephrologist at LUMC and has a passion for autoimmune diseases and improving their treatment. He is head of the Nephrology Outpatient clinic and coordinator of the Leiden outpatient clinic for Lupus, Vasculitis and Complement-mediated Systemic diseases. My ambition is to achieve that patients with a rare systemic autoimmune disease profit from all the wonderful and dedicated physicians that share their expertise for the patient’s well-being. Shared Care and Care to Share!

Maarten Limper
Chair working group APS

Maarten is internist-clinical immunologist at UMC Utrecht. He is also secretary of the national working group for SLE and member of the EULAR APS task force, is active in the European Reference Network for rare connective tissue disorders (ERF-ReConnet) and member of the European Autoimmunity Standardization Initiative (EASI). His clinical and research work revolve around APS and SLE. “I want every APS patient in the Netherlands to get the right information and treatment without any unnecessary delays.”

Julia Spierings
Project Manager

Julia works as a rheumatologist and researcher at UMC Utrecht since 2017. She is focussing on systemic autoimmune diseases, especially systemic sclerosis. She was trained in Eindhoven, Maastricht, Heerlen and Utrecht and was chair of the Junior Dutch Society for Rheumatology. “The care provided for rare forms of arthritis should be organized in such a way that patients can live their lives confidently.”

Lieke van Mourik
Project Manager

Lieke is a health scientist and graduated in health education. She has worked for organisations such as the Dutch Cancer Society, the Municipal Health Service and the Regional Medical Assistance Organisation. At the Dutch Cancer Society she was team manager of the Prevention team, More Cure team, Better Quality of Life team and of Patient Support. “With all the relevant expertise being brought together in ARCH, patients can get a clearer picture of their diagnosis and possible treatments more quickly.”




Peter Verhoeven (AAV), Dirk van der Heijden (SSc) and Rita Schriemer (SSc) joined the project team in October 2018. As previous members of ARCH working groups and the pilot group, they were already familiar with the ARCH approach.


Centers of expertise

There are eight university medical centres (umcs) in the Netherlands. Each of these centres of expertise is closely involved in the development of ARCH.

  • AMC, Academic Medical Center Amsterdam
  • Erasmus MC, Erasmus MC Rotterdam
  • LUMC, Leiden University Medical Center Leiden
  • Maastricht UMC+, Maastricht UMC+
  • UMCG, University Medical Center Groningen
  • Radboudumc, Radboud University Medical Center Nijmegen
  • UMC Utrecht, University Medical Center Utrecht
  • VUmc, VU Medical Center Amsterdam